10 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 20 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 10, Active not recruiting 3, Recruiting 2, Terminated 2, Unknown 2, Withdrawn 1 |
| Phase 2 | 1 | Completed 1 |
Follow Polymyalgia Rheumatica: new trials by email Literature Review of Polymyalgia Rheumatica trials Research Report on Polymyalgia Rheumatica
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica Sarilumab, Placebo - Polymyalgia Rheumatica | Phase 3 | Recruiting | Sanofi | 300 | 2026-05-12 | 2026-10-21 |
| Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica Baricitinib 4 MG Oral Tablet, Baricitinib 2 MG Oral Tablet, Placebo 4 mg - Polymyalgia Rheumatica (PMR) | Phase 3 | Recruiting | University Hospital, Brest | 140 | 2025-12-18 | 2026-08-26 |
| Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) Olokizumab, Placebo - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | R-Pharm International, LLC | 125 | 2025-06-11 | 2026-06-30 |
| Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) Secukinumab - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 162 | 2024-06-28 | 2026-10-14 |
| Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica Prednisone+Tofacitinib, Prednisone - Polymyalgia Rheumatica | Phase 3 | Completed | Zhejiang University | 104 | 2024-01-20 | 2026-09-08 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab - Polymyalgia Rheumatica | Phase 3 | Completed | Novartis Pharmaceuticals | 381 | 2023-03-22 | 2026-06-22 |
| Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse Rituximab, Placebo - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | Sint Maartenskliniek | 174 | 2023-02-09 | 2026-02-04 |
| Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed Rituximab, Placebo - Polymyalgia Rheumatica | Phase 3 | Completed | Sint Maartenskliniek | 114 | 2023-02-01 | 2026-02-03 |
| Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c. - Giant Cell Arteritis | Phase 3 | Completed | Novartis Pharmaceuticals | 151 | 2022-09-29 | 2026-02-27 |
| Treatment With Leflunomide in Patients With Polymyalgia Rheumatica Leflunomide 20 mg, Prednisolone - Polymyalgia Rheumatica | Phase 3 | Unknown | Elisabeth Brouwer | 94 | 2019-03-01 | 2019-06-03 |
| Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS Abatacept, Placebos - Polymyalgia Rheumatica | Phase 3 | Completed | University Hospital, Brest | 34 | 2018-12-13 | 2026-06-08 |
| Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone - Polymyalgia Rheumatica | Phase 3 | Terminated | Sanofi | 118 | 2018-10-09 | 2022-06-10 |
| Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Sirukumab, Placebo to match sirukumab, Prednisone /Prednisone placebo - Polymyalgia Rheumatica | Phase 3 | Withdrawn | GlaxoSmithKline | 2018-03-15 | 2017-11-20 | |
| A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Tocilizumab Prefilled Syringe [Actemra], Placebos, Glucocorticoids - Polymyalgia Rheumatica | Phase 3 | Completed | Medical University of Vienna | 39 | 2017-11-24 | 2021-01-22 |
| Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Tocilizumab, Placebo - Polymyalgia Rheumatica | Phase 3 | Completed | University Hospital, Brest | 113 | 2017-02-15 | 2020-12-04 |
| A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Lodotra®, Prednisone IR (immediate release) - Polymyalgia Rheumatica | Phase 3 | Terminated | Mundipharma Research Limited | 62 | 2013-03-01 | 2018-10-24 |
| Timed Release Tablet Prednisone in Polymyalgia Rheumatica Timed Release Tablet Prednisone, Prednisolone - Polymyalgia Rheumatica | Phase 2 / Phase 3 | Completed | University Hospitals Bristol and Weston NHS Foundation Trust | 12 | 2009-10-01 | 2022-09-13 |
| Etanercept Treatment in the Early Course of Polymyalgia Rheumatica Etanercept (Enbrel), Sodium chloride (placebo) - Polymyalgia Rheumatica | Phase 3 | Completed | Bispebjerg Hospital | 40 | 2007-08-01 | 2010-02-23 |
| Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica infliximab, inactive powder - Polymyalgia Rheumatica | Phase 3 | Unknown | Hospital Universitario Marqués de Valdecilla | 23 | 2007-06-01 | 2011-08-26 |
| Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Alendronate versus alfacalcidol (1-alpha OH vitamin D) - Rheumatoid Arthritis, Polymyalgia Rheumatica | Phase 3 | Completed | UMC Utrecht | 200 | 2000-05-01 | 2006-11-29 |
Giant Cell Arteritis (2) · Arteritis (1) · Arthritis, Rheumatoid (1) · Granulomatosis with Polyangiitis (1) · Polymyositis (1) · Rheumatic Diseases (1) · Vascular Diseases (1) · Vasculitis (1)
Connective Tissue Diseases (20) · Muscular Diseases (20) · Musculoskeletal Diseases (20) · Skin and Connective Tissue Diseases (20) · Rheumatic Diseases (19) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Brain Diseases (2) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Cerebrovascular Disorders (2) · Immune System Diseases (2) · Nervous System Diseases (2) · Skin Diseases (2) · Skin Diseases, Vascular (2)
Prednisone (3) · secukinumab (3) · Prednisolone (2) · Rituximab (2) · sarilumab (2) · tocilizumab (2) · Abatacept (1) · Etanercept (1) · Glucocorticoids (1) · Infliximab (1) · Leflunomide (1) · Sodium Chloride (1) · Tablets (1) · baricitinib (1) · olokizumab (1)
Novartis Pharmaceuticals (3) · University Hospital, Brest (3) · Sanofi (2) · Sint Maartenskliniek (2) · Bispebjerg Hospital (1) · Elisabeth Brouwer (1) · GlaxoSmithKline (1) · Hospital Universitario Marqués de Valdecilla (1) · Medical University of Vienna (1) · Mundipharma Research Limited (1) · R-Pharm International, LLC (1) · UMC Utrecht (1) · University Hospitals Bristol and Weston NHS Foundation Trust (1) · Zhejiang University (1)
Netherlands (8) · France (7) · Germany (5) · Spain (5) · United Kingdom (5) · Belgium (4) · Canada (4) · United States (4) · Argentina (3) · Australia (3) · Czechia (3) · Denmark (3) · Hungary (3) · Italy (3) · Japan (3)
Aatke van der Maas (1) · Aatke van der Maas, MD PhD (1) · E.M. Colin (1) · Elisabeth Brouwer (1) · Henrik Galbo, Professor (1) · John R Kirwan, MBBS,MD,FRCP (1) · Mikhail Samsonov (1) · Vicente Rodriguez-Valverde, MD, PhD (1)
PMID 39400109, PMID 16914703, PMID 17407214, PMID 17557758, PMID 20854662, PMID 22894827, PMID 35210264, PMID 36125471, PMID 37792612, PMID 38095675, PMID 38251563, PMID 40544861, PMID 42234540
2016 (1), 2017 (1), 2023 (1)